Study Unable to Rule Out Link Between TNF Inhibitors and Cancer Risk

By Kerri Fitzgerald - Last Updated: August 14, 2018

A study published in the Annals of Internal Medicine found that treatment with tumor necrosis factor TNF inhibitors is not associated with increased risk for cancer recurrence in patients with rheumatoid arthritis (RA); however, the researchers said, “meaningful risk increases could not be ruled out completely.” 

Advertisement

Researchers conducted a population-based cohort study and used nationwide registries (including the Swedish National Patient Register, Swedish Prescribed Drug Register, Swedish Cancer Registry, Swedish Population Register, National Register of Education, and Swedish Cause of Death Register) to identify patients with RA who started TNF inhibitor treatment between 2001 and 2015 after being diagnosed with cancer (n=467). They matched them to a cohort with RA and a history of the same cancer who had never been treated with biologics (n=2,164). 

Among those who received TNF inhibitors, 42 had cancer recurrences (9%), while 155 patients in the matched cohort had recurrences (7.2%; hazard ratio [HR] = 1.06; 95% CI, 0.73-1.54). “HRs were close to one in analyses of patient subsets matched on cancer stage or with similar time from index cancer diagnosis to the start of TNF inhibitor treatment, as well as in unmatched analyses,” the authors noted. “Several CIs had upper limits close to two. 

Read about the impending results of a study about cancer risk from living near atomic bomb test site. 

The FDA recalled a heart medicine for its cancer risk. 

Is dinner time related to cancer risk? 

Source: Annals of Internal Medicine 

Advertisement